|
| GSK269962A Basic information |
Product Name: | GSK269962A | Synonyms: | GSK 269962;N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide;GSK269962A(GSK269962);N-(3-((2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl)oxy)phenyl)-4-(2-morpholinoethoxy)benzamide;CS-1126;N-[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]benzamide;ROCK inhibitor GS269962A;GSK 269962A;GSK-269962A;GSK269962;GSK 269962;GSK-269962 | CAS: | 850664-21-0 | MF: | C29H30N8O5 | MW: | 570.6 | EINECS: | | Product Categories: | | Mol File: | 850664-21-0.mol | |
| GSK269962A Chemical Properties |
Melting point | 125 - 127°C | density | 1.45 | storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | solubility | DMSO (Slightly), Methanol (Slightly) | form | Solid | pka | 13.19±0.70(Predicted) | color | Off-White |
| GSK269962A Usage And Synthesis |
Description | Two Rho-associated kinases (ROCKS), ROCK1 and ROCK2, act downstream of the G protein Rho to regulate cytoskeletal stability. The ROCKs play important roles in diverse cellular functions including cell adhesion and proliferation, smooth muscle contraction, and stem cell renewal. GSK269962 is a selective ROCK inhibitor with IC50 values of 1.6 and 6 nM for ROCK1 and ROCK2, respectively. It displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. GSK269962 has been shown to block the generation of inflammatory cytokines in lipopolysaccharide-stimulated monocytes and to induce vasorelaxation in preconstricted rat aorta (IC50 = 35 nM). Oral administration of 1-30 mg/kg GSK269962 can dose-dependently lower blood pressure in spontaneously hypertensive rats. | Uses | GSK 269962 is a potent and selective Rho kinase (ROCK) inhibitor. | storage | Store at +4°C |
| GSK269962A Preparation Products And Raw materials |
|